Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $160 from $92 and keeps a Buy rating on the shares after updating the firm’s model to reflect updated assumptions for daraxonrasib and now incorporating probability-adjusted estimates for zoldonrasib, reflecting increased visibility on Revolution’s Phase 3 development plans across pancreatic and lung cancers, respectively.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
- Expanding RAS-Targeted Franchise and Late-Stage Pipeline Drive Buy Rating on Revolution Medicines
- Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s
- Revolution Medicines: Clinical Momentum and Strategic Phase 3 Design Support Buy Rating on RVMD
- Revolution Medicines price target raised to $143 from $90 at Mizuho